B
Bull
Bull · 25%ONCY
$1.63
Precio del escenario
$0.840
+0.002 (+0.21%)Al cierre
Loading chart…
- High
- 0.857
- Open
- 0.831
- VWAP
- 0.84
- Vol
- 435.58K
- Mkt Cap
- 76.17M
- Low
- 0.825
- Amount
- 366.25K
- EV/EBITDA, TTM
- 0.00
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically cold tumors hot through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers.
AI analysis of Oncolytics Biotech Inc (ONCY)
buyOncolytics Biotech Inc is a good buy right now due to its recent patent acquisition and FDA Fast Track designation, which enhance its market position. The current price is $0.86, and the RSI is at 61.82, indicating bullish momentum. However, the company has reported significant losses, with a net income of -12,679,060.40 CAD in Q1 2026, which poses a risk to its financial stability.
Métricas de valoración
The current forward P/E ratio for Oncolytics Biotech Inc (ONCY) is 45.45, compared to its 5-year average forward P/E of 2.70.
Alphio AI Price Scenarios for ONCY
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.008-18NewsfilterFDA Feedback Supports Expansion of REO 033 Study
9.007-21NASDAQ.COMOncolytics Receives FDA Fast Track Designation for Pelareorep
- 9.007-20Newsfilter
Oncolytics Receives FDA Fast Track Designation for Pelareorep
- 9.007-14Newsfilter
Oncolytics Biotech Provides Clinical Update on REO 033 Trial
9.007-13NASDAQ.COMOncolytics Biotech Provides Clinical Update on REO 033 for Colorectal Cancer
ONCY FAQ — answered by Alphio AI
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a range of oncology treatments. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically cold tumors hot through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Oncolytics Biotech Inc is a good buy right now due to its recent patent acquisition and FDA Fast Track designation, which enhance its market position. The current price is $0.86, and the RSI is at 61.82, indicating bullish momentum. However, the company has reported significant losses, with a net income of -12,679,060.40 CAD in Q1 2026, which poses a risk to its financial stability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.